摘要
目的:探讨Ⅳ期非小细胞肺癌(NSCLC)βⅢ-tubulin表达与紫杉类化疗耐药性关系.方法:回顾性分析75例接受以紫杉类化疗的Ⅳ期NSCLC临床病理资料.免疫组织化学法检测肿瘤标本βⅢ-tubulin蛋白表达,并对化疗疗效及生存时间进行分析.结果:βⅢ-tubulin阳性表达率(≥50%阳性染色细胞)为58.7%(44/75),与性别、年龄及组织类型无关.化疗有效率(CR+PR)为34.7%,βⅢ-tubulin高表达患者紫杉类化疗有效率低(25.0%),进展率高(25.0%),而βⅢ-tubulin低表达患者化疗有效率高(48.9%),进展率低(6.4%),P值分别为0.036和0.037.βⅢ-tubulin高表达者有较短的中位OS(12 mo)和PFS(8 mo),而βⅢ-tubulin低表达患者有较长的中位总生存期(OS)(15 mo)和无进展生存期(PFS)(11 mo),P=0.018.结论:βⅢ-tubulin高表达NSCLC患者对紫杉类药物耐药且预后不良.
AIM： To investigatethe the relationship between the expression of βⅢ-tubulin protein and chemoresistance to taxane in non-small cell lung cancer （NSCLC）. METHODS： Seventy-five patients with stage Ⅳ NSCLC treated with taxane were enrolled in this study and their clinical data were analyzed retrospectively. The expression of βⅢ-tubulin protein in tumor samples was detected by the immunohistochemical methods. The data of therapeutical effect and survival time were collected and analyzed. RESULTS： The βⅢ-tubulin positive staining rate （≥ 50% of stained cells） accounted for 58.7% （44/75）. There was no correlation between βⅢ-tubulin positive expression and age, gender, and pathological type. The response rate （ CR ＋ PR） was 34.7%. Patients with βⅢ-tubulin overexpression displayed less response rate and more progression rate to taxane （ response rate 25.0%, PD 25.0% in patients with t〉 50% of stained cells vs response rate 48.89%, PD 6.5% in patients with 〈 50%, P = 0.036 and P = 0.037, respectively）. Overexpression of βⅢ-tubulin protein expression was correlated with shorter median overall survival （ 12 months） and progression-free survival （8 months）, While a low level of βⅢ-tubtdin protein expression was correlated with longer median overall survival （ 15 months） and progression-free survival （ 11 months ） , P = 0. 018. CONCLUSION ： Overexpression of βⅢ-tubulin in tumor cells is associated with resistance to taxane and a poor prognosis in patients with NSCLC receiving taxane - based chemotherapy.
出处
《第四军医大学学报》
北大核心
2008年第10期930-932,共3页
Journal of the Fourth Military Medical University
基金
河北省科技支撑计划项目(072761486)
关键词
非小细胞肺癌
紫杉醇
微管蛋白
抗药性
免疫组织化学
non-small cell lung cancer
paclitaxel
tubulin
drug resistance： immunohistechemistrv
